Novozymes A/S – ADR ( (NVZMY) ) has released its Q4 earnings. Here is a breakdown of the information Novozymes A/S – ADR presented to its investors.
Novozymes A/S – ADR, now part of the Novonesis Group, is a leading biotechnology company specializing in sustainable biosolutions across various industries, including food, health, and planetary health.
In its latest earnings report, Novozymes A/S reported an 8% organic pro forma sales growth for 2024, with a pro forma adjusted EBITDA margin of 36.1%. The company has set a 2025 outlook with an expected organic sales growth of 5-8% and an adjusted EBITDA margin of 37-38%.
The company’s Food & Health Biosolutions segment achieved a 7% organic sales growth, driven by strong performances in Food & Beverages and Human Health. Meanwhile, the Planetary Health Biosolutions segment saw a 9% growth, with significant contributions from Household Care and Agriculture, Energy & Tech. Novozymes also announced a EUR 100 million share buyback program for 2025 and launched 45 new innovations during the year.
Looking ahead, Novozymes expects continued strong performance in 2025, with growth anticipated across all segments. The company plans to reinvest significantly to support growth, particularly in markets with high potential. The management remains optimistic about achieving its financial targets, driven by a diversified portfolio and strategic initiatives.